Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.5621
-0.0369 (-6.16%)
Aug 10, 2026, 4:00 PM EDT - Market closed
Barinthus Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
22.96M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 14.97M | 14.17M | 1,766.46% |
| Dec 31, 2023 | 802.00K | -43.90M | -98.21% |
| Dec 31, 2022 | 44.70M | 44.44M | 16,580.22% |
| Dec 31, 2021 | 268.00K | -4.55M | -94.44% |
| Dec 31, 2020 | 4.82M | -2.02M | -29.57% |
| Dec 31, 2019 | 6.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Actinium Pharmaceuticals | 35.09M |
| Evaxion | 7.53M |
| Longeveron | 1.22M |
| IGC Pharma | 1.11M |
| ABVC BioPharma | 797.92K |
| Allarity Therapeutics | 345.00K |
BRNS News
- 4 days ago - Barinthus Biotherapeutics price target lowered to $6 from $7 at Alliance Global - TheFly
- 4 days ago - Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 4 days ago - Barinthus Biotherapeutics Quarterly report: Q2 2026 - Filings
- 4 days ago - Barinthus Biotherapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Barinthus Biotherapeutics Proxy statement: Proxy filing - Filings
- 3 months ago - Barinthus Biotherapeutics Proxy statement: Proxy filing - Filings
- 3 months ago - Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 3 months ago - Barinthus Biotherapeutics Earnings release: Q1 2026 - Filings